# Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia

> **NCT01467661** · PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 41 (actual)

## Conditions studied

- Essential Thrombocythemia (ET)

## Interventions

- **DRUG:** SPD422 (anagrelide hydrochloride)

## Key facts

- **NCT ID:** NCT01467661
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-27
- **Primary completion:** 2015-05-01
- **Final completion:** 2015-05-01
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2021-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01467661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01467661, "Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01467661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*